• Welcome to Tamil Brahmins forums.

    You are currently viewing our boards as a guest which gives you limited access to view most discussions and access our other features. By joining our Free Brahmin Community you will have access to post topics, communicate privately with other members (PM), respond to polls, upload content and access many other special features. Registration is fast, simple and absolutely free so please, join our community today!

    If you have any problems with the registration process or your account login, please contact contact us.

Novartis buys GSK's cancer drugs for $14.5 billion in a 3-way deal

Status
Not open for further replies.

Novartis buys GSK's cancer drugs for $14.5 billion in a 3-way deal




LONDON: Amidst a flurry of consolidation in the pharma industry, global pharmaceutical giants GlaxoSmithKline and Novartis announced a massive three way deal that will see the rivals exchanging asset portfolios, and merging the consumer health businesses in a new joint venture.

GSK will sell its portfolio of cancer drugs to Novartis for $14.5 billion, plus another $1.5 billion, depending on trials in progress.

Novartis in turn, sells its vaccines portfolio, except flu, to GSK for $5.25 billion.
Separately, Novartis also sold its animal health business to the American Eli Lilly for $5.4 billion, which will make Eli Lilly world number 2 in animal health.


GSK and Novartis will pool their assets in consumer health with a new JV, with pro-forma combined turnover of $6.5 billion, in which GSK will have majority control with 63.5%.


However, a spokesperson for GSK clarified that GSK's India consumer health business is not included in the new JV, and will continue to operate as usual. Its acquisition of Novartis' vaccine business will also give GSK new manufacturing facilities in India.


GSK said that the proposed transaction will boost GSK's annual revenues by £1.3 billion to £26.9 billion (on a 2013 pro-forma basis), split across pharmaceuticals 62%, consumer healthcare 24% and vaccines 14%.


The mega deal comes even as global pharma majors are struggling with low growth, and streamlining their operations as governments cut down on health spending. GSK is not a world leader in oncology, and analysts said it made sense for the company to exit the highly competitive cancer arena.

Similarly, Novartis hopes to benefit from exiting low-margin vaccine business for high margin cancer drugs. In India, this news sent Novartis stock price soaring by 10% during intraday trading. At the end of Tuesday's trade the company's stock closed at Rs 497 up 6% at BSE.


Novartis buys GSK's cancer drugs for $14.5 billion in a 3-way deal - The Economic Times
 
Status
Not open for further replies.

Latest ads

Back
Top